• Les complications cardiovasculaires sous inhibiteurs de BTK

    Réf :HematoStat.net ; 2 (7) : V60 Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, Martinez-Calle N, […]

    Published On: 12 July 2022

  • Caryotype complexe et LLC

    Réf :HematoStat.net ; 2 (7) : V59 Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Rigolin GM, Del Giudice I, […]

    Published On: 12 July 2022

  • Un espoir dans le Richter ?

    Réf :HematoStat.net ; 2 (7) : V58 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, […]

    Published On: 12 July 2022

  • Le stade A reste le stade A !

    Réf :HematoStat.net ; 2 (7) : V57 The CLL12 trial: ibrutinib vs. placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf […]

    Published On: 12 July 2022

  • Cinétique de la MRD

    Published On: 12 July 2022

  • La MRD mais pourquoi si tôt ?

    Published On: 12 July 2022

  • Acalabrutinib vs ibrutinib en traitement des patients déjà traités pour une LLC : résultats du premier essai randomisé de phase 3

    Published On: 15 May 2022

  • LA P-VALUE !

    Published On: 28 April 2022

  • Qualité de vie, enfin un outil dédié de l’EORTC pour la LLC

    Réf :HematoStat.net ; 2 (4) : V56 EORTC Quality of Life Group. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic […]

    Published On: 27 April 2022

  • Hématopoièse clonale avant immunochimiothérapie ?

    Réf :HematoStat.net ; 2 (4) : V55 Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. Voso MT, Pandzic T, […]

    Published On: 27 April 2022